Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Equity (2018 - 2025)

Crinetics Pharmaceuticals has reported Return on Equity over the past 8 years, most recently at 0.45% for Q4 2025.

  • Quarterly results put Return on Equity at 0.45% for Q4 2025, down 17.0% from a year ago — trailing twelve months through Dec 2025 was 0.45% (down 17.0% YoY), and the annual figure for FY2025 was 0.4%, down 8.0%.
  • Return on Equity for Q4 2025 was 0.45% at Crinetics Pharmaceuticals, down from 0.38% in the prior quarter.
  • Over the last five years, Return on Equity for CRNX hit a ceiling of 0.25% in Q1 2025 and a floor of 0.69% in Q2 2023.
  • Median Return on Equity over the past 5 years was 0.4% (2022), compared with a mean of 0.42%.
  • Biggest five-year swings in Return on Equity: decreased -30bps in 2023 and later surged 39bps in 2024.
  • Crinetics Pharmaceuticals' Return on Equity stood at 0.41% in 2021, then decreased by -20bps to 0.49% in 2022, then rose by 21bps to 0.38% in 2023, then increased by 28bps to 0.28% in 2024, then tumbled by -63bps to 0.45% in 2025.
  • The last three reported values for Return on Equity were 0.45% (Q4 2025), 0.38% (Q3 2025), and 0.3% (Q2 2025) per Business Quant data.